Biogen Idec

Biogen Idec 4Q10

4Q10 Revenues: $1.2 billion (+8%)

4Q10 Earnings: $272 million (-11%)

FY Revenues: $4.7 billion (+8%)

FY Earnings: $899 million (-8%)

Comments: Avonex sales rose 8% for the year to $2.5 billion and 10% for 4Q10 to $654 million. Tysabri revenues rose 16% for FY to $900 million and 12% to $242 million in 4Q10. Tysabri sales were split nearly 50/50 between U.S. and non-U.S. markets. Rituxan revenues dropped 2% to $1.1 billion for the year, due to expiration of royalties on non-U.S. sales